Literature DB >> 11799967

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.

Marcello Persico, Fedele De Marino, Giovanni Di Giacomo Russo, Aristide Morante, Bruno Rotoli, Roberto Torella, Amalia De Renzo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11799967     DOI： 10.1182/blood.v99.2.724

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  20 in total

1.  Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients.

Authors:  E Persico; A De Renzo; V La Mura; S Bruno; M Masarone; R Torella; M Persico
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

2.  Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.

Authors:  C-K Hui; W W W Cheung; W-Y Au; A K W Lie; H-Y Zhang; Y-H Yueng; B C Y Wong; N Leung; Y-L Kwong; R Liang; G K K Lau
Journal:  Gut       Date:  2005-07-06       Impact factor: 23.059

3.  Management of hepatitis B reactivation in patients receiving cancer chemotherapy.

Authors:  Yi-Wen Huang; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

4.  Hepatitis B reactivation after chemotherapy: two decades of clinical research.

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

5.  A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma.

Authors:  Toru Takahashi; Tadashi Koike; Shigeo Hashimoto; Tomofumi Miura; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Kazuhide Yamazaki; Shogo Okoshi; Yutaka Aoyagi
Journal:  Hepatol Int       Date:  2008-09-23       Impact factor: 6.047

6.  Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.

Authors:  In Kyoung Kim; Byeong Gwan Kim; Won Kim; Donghee Kim; Yoon Jun Kim; Jung-Hwan Yoon; Hyo Suk Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

7.  Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement.

Authors:  R Lee; K Vu; C M Bell; L K Hicks
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

8.  Reactivation of hepatitis B: pathogenesis and clinical implications.

Authors:  Anthony Post; Shweta Nagendra
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

9.  Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.

Authors:  Daisuke Shimizu; Kenichi Nomura; Yosuke Matsumoto; Kyoji Ueda; Kanji Yamaguchi; Masahito Minami; Yoshito Itoh; Shigeo Horiike; Masuji Morita; Masafumi Taniwaki; Takeshi Okanoue
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

10.  Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.

Authors:  Panayiotis D Ziakas; Petros Karsaliakos; Eleftherios Mylonakis
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.